The launch of hepatitis C (HCV) drugs such as sofosbuvir or ledipasvir has fostered the question of affordability of novel high budget impact therapies even in countries with high domestic product. European countries have developed a variety of mechanisms to improve affordability of such therapies, including ‘affordability thresholds’, price volume agreements or caps on individual […]
The role of forecasting as a business function, or if used as a tool in and outside of Pharma / Device organisations, continues to evolve at a fast pace. Ben Collins (Boehringer Ingelheim) and Erik Holzinger (groupH) are hosting a round-table discussion during this year’s annual EphMRA 2018 Conference in Basel, to open up a […]
As we’re sure you are aware, the biggest healthcare investing event of the year, the JP Morgan Healthcare Conference, will be returning to San Francisco in early January. groupH will be attending the Biotech Showcase – navigating the packed agenda of company presentations, panel discussions, and networking receptions. If you’re in San Francisco for these […]
Longing for time to browse through a book like ‘The Little Prince’ after a hectic December inspired this year’s End-of-Year card drawing by our London based designer, Yasmin El Saie. One line in the book reads: ‘Grown-ups never understand anything on their own, and it’s a nuisance for children to have to keep explaining things […]
This new two-day conference allowed for honest discussions in small groups helped by the simple set-up and high-quality contributions from both payers and industry. Our head of market access, Nicolas Touchot chaired a keynote panel on Preferred Payment Models for cell and gene therapies. The news of Kite’s CAR-T US approval coming in at $373,000 […]
This is indeed a question many people ask, or if not, should ask themselves. With forecasts even at late-stage clinical development, and assuming the product is approved, launched and reimbursed, peak sales can be more than ten years into the future. This does not naturally invite follow-up or analysis as people and organisations move on […]
Join groupH at EphMRA 2017 in Amsterdam between 20-22 June. Erik Holzinger will be chairing several sessions and also co-presenting with Bernd Mühlenweg from Nanobiotix. Their session will explore the benefits of addressing the payer hurdle very early in clinical development, and will focus on sharing ideas and best practice. “How engaging payers early transformed our clinical […]
…together Whether virtually working together or not, it is the people who are the basis of any venture. You only know who you and your colleagues really are when stepping outside your day-to-day comfort zone. And what could be more outside our comfort zone than composing and singing a song for a music video? Many […]
